ArticleNeuro-oncology advances
Long-term outcomes of active surveillance after DOTATATE PET/MRI-confirmed gross total resection in WHO grade 2 meningioma.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Brain Tumor Imaging Beyond [AJR. American journal of roentgenology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Somatostatin receptor 2 (SSTR2), a highly sensitive and specific meningioma biomarker, can be imaged with [68Ga]-DOTATATE PET, improving diagnosis and treatment. The role of postoperative radiotherapy (RT) for WHO grade 2 (WHO-2) meningiomas following gross total resection (GTR) remains controversial. We hypothesized that confirmation of GTR by DOTATATE PET/MRI followed by active surveillance would yield superior progression-free survival (PFS) compared to MRI-based GTR assessment alone. Methods: Patients with WHO-2 meningioma enrolled in a prospective registry were included if postoperative PET/MRI showed GTR and if they were managed with surveillance alone. All patients underwent serial MRI and/or PET/MRI follow-up. Kaplan-Meier analysis was used to determine PFS. A retrospective institutional comparator cohort of patients with WHO-2 meningiomas and MRI-determined GTR managed with surveillance alone was also evaluated. Results: Twenty-eight prospective subjects (61% women, mean age 61 years) met inclusion criteria. Meningiomas were located along the convexity (50%), falx (21%), and skull base (29%). Mean mitotic count was 5.1 per 10 high-power fields; mean follow-up was 28 months (range 5-64). In the PET/MRI cohort, PFS was 90.0% at 5 years. In comparison, the MRI-only cohort ( Conclusions: DOTATATE PET/MRI-confirmed GTR followed by active surveillance yielded significantly higher PFS compared to MRI-based GTR assessment in patients with WHO-2 meningioma. DOTATATE PET/MRI increases diagnostic certainty, enabling more accurate postoperative risk stratification and potentially avoiding unnecessary RT, supporting its integration into postoperative decision-making for WHO-2 meningioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.